B+
Bull case
20%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
MDXG
MiMedx GroupBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$4.80
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$3.20
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-25
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+63.0
Score
AI commentary
News tone is mixed-positive after the Q2 update, supported by Surgical growth, improving Wound volumes, guidance reaffirmation, and the Sanara announcement. Negative operating trends, reimbursement pressure, margin deterioration, financing risk, and absent post-release market-reaction or analyst-revision data keep the thesis in monitoring territory. Social coverage is unavailable.
RankAlpha Sentiment Codex - 2026-08-25
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-29eventQ2 operating update and FY2026 guidance reaffirmationHigh impact
Q2 net sales were $64 million; Surgical sales grew 15% year over year and Wound volume grew 22% sequentially. Management reaffirmed standalone FY2026 net-sales guidance of $260-$290 million, but total sales declined 35% and Wound sales declined 61%. [#SEC-8K-2026-07-29]
2026-11-15catalystWound reimbursement and margin normalization riskHigh impact
Medicare reimbursement changes pressured Wound pricing and mix; gross margin fell to 69% from 81%, and the company reported a $15 million quarterly net loss. Further stabilization is unproven. [#SEC-8K-2026-07-29]
2027-08-25catalystSanara MedTech acquisition and surgical expansionHigh impact
MiMedx announced a definitive agreement to acquire Sanara for approximately $350 million of enterprise value, financed partly with a planned $300 million term loan. Successful execution could broaden the surgical franchise, but financing and integration increase risk. [#SEC-8K-2026-07-29]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-25 • Updated nightlySource: Internal modelMethodology